Graham Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Graham Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Sell	15,324 -3,161	-17%	-$50.9K	0.01%	919
2026 Q1	$362K	Sell	18,485 -6,344	-26%	-$188K	0.01%	739
2025 Q4	$773K	Sell	24,829 -12,661	-34%	-$347K	0.02%	463
2025 Q3	$809K	Sell	37,490 -17,706	-32%	-$319K	0.01%	447
2025 Q2	$772K	Buy	55,196 +37,013	+204%	+$502K	0.01%	668
2025 Q1	$245K	Buy	18,183 +5,283	+41%	+$90K	﹤0.01%	1066
2024 Q4	$247K	Sell	12,900 -1,533	-11%	-$33.3K	﹤0.01%	1009
2024 Q3	$328K	Sell	14,433 -8,011	-36%	-$131K	0.01%	751
2024 Q2	$292K	Buy	+22,444	New	+$311K	0.01%	745

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Graham Capital Management's VRDN Position: Q2 2026 in Review

Graham Capital Management reduced its Viridian Therapeutics (VRDN) stake by 17% in Q2 2026, selling an estimated $50.9K and leaving 15,324 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #919.

Graham Capital Management first reported a position in VRDN in Q2 2024 and has held it in 9 quarters since. The position peaked at $809K in Q3 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Graham Capital Management held 15,324 shares of Viridian Therapeutics worth $282K as of Q2 2026.
Graham Capital Management sold 3,161 Viridian Therapeutics shares in Q2 2026, an estimated $50.9K.
Viridian Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #919 holding.
Graham Capital Management first reported a position in Viridian Therapeutics in Q2 2024 and has held it in 9 quarters since.
Graham Capital Management's Viridian Therapeutics position peaked at $809K in Q3 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.